219 related articles for article (PubMed ID: 38531378)
21. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Castro Narro GE; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN;
Hepatology; 2023 Dec; 78(6):1966-1986. PubMed ID: 37363821
[TBL] [Abstract][Full Text] [Related]
22. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
[TBL] [Abstract][Full Text] [Related]
23. Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.
Suzuki K; Tamaki N; Kurosaki M; Takahashi Y; Yamazaki Y; Uchihara N; Tanaka Y; Miyamoto H; Yamada M; Keitoku T; Okada R; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Tsuchiya K; Nakanishi H; Izumi N
Hepatol Res; 2024 Jun; 54(6):600-605. PubMed ID: 38234088
[TBL] [Abstract][Full Text] [Related]
24. [Not Available].
Hansen CD; Lindvig KP; Grønbæk H; Gluud LL; Thiele M; Krag A
Ugeskr Laeger; 2024 May; 186(19):. PubMed ID: 38808766
[TBL] [Abstract][Full Text] [Related]
25. New concept in fatty liver diseases.
Tokushige K
Hepatol Res; 2024 Feb; 54(2):125-130. PubMed ID: 38146790
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020.
Kalligeros M; Vassilopoulos A; Vassilopoulos S; Victor DW; Mylonakis E; Noureddin M
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1330-1332.e4. PubMed ID: 37949334
[TBL] [Abstract][Full Text] [Related]
27. [Fatty liver disease's renaming impacts on drug clinical trials].
Huang R; Rao HY
Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):793-797. PubMed ID: 37723059
[TBL] [Abstract][Full Text] [Related]
28. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
Lee CM; Yoon EL; Kim M; Kang BK; Cho S; Nah EH; Jun DW
Hepatology; 2024 Jun; 79(6):1393-1400. PubMed ID: 38100294
[TBL] [Abstract][Full Text] [Related]
29. Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics.
Jiang Y; Wu L; Zhu X; Bian H; Gao X; Xia M
Lipids Health Dis; 2024 Apr; 23(1):95. PubMed ID: 38566209
[TBL] [Abstract][Full Text] [Related]
30. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T
Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684
[TBL] [Abstract][Full Text] [Related]
31. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
[TBL] [Abstract][Full Text] [Related]
32. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
Younossi ZM; Alqahtani SA; Alswat K; Yilmaz Y; Keklikkiran C; Funuyet-Salas J; Romero-Gómez M; Fan JG; Zheng MH; El-Kassas M; Castera L; Liu CJ; Wai-Sun Wong V; Zelber-Sagi S; Allen AM; Lam B; Treeprasertsuk S; Hameed S; Takahashi H; Kawaguchi T; Schattenberg JM; Duseja A; Newsome PN; Francque S; Spearman CW; Castellanos Fernández MI; Burra P; Roberts SK; Chan WK; Arrese M; Silva M; Rinella M; Singal AK; Gordon S; Fuchs M; Alkhouri N; Cusi K; Loomba R; Ranagan J; Eskridge W; Kautz A; Ong JP; Kugelmas M; Eguchi Y; Diago M; Yu ML; Gerber L; Fornaresio L; Nader F; Henry L; Racila A; Golabi P; Stepanova M; Carrieri P; Lazarus JV;
J Hepatol; 2024 Mar; 80(3):419-430. PubMed ID: 37984709
[TBL] [Abstract][Full Text] [Related]
33. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
[TBL] [Abstract][Full Text] [Related]
34. Update in lean metabolic dysfunction-associated steatotic liver disease.
Sato-Espinoza K; Chotiprasidhi P; Huaman MR; Díaz-Ferrer J
World J Hepatol; 2024 Mar; 16(3):452-464. PubMed ID: 38577539
[TBL] [Abstract][Full Text] [Related]
35. Waiting for the changes after the adoption of steatotic liver disease.
Yoon EL; Jun DW
Clin Mol Hepatol; 2023 Oct; 29(4):844-850. PubMed ID: 37670441
[TBL] [Abstract][Full Text] [Related]
36. The Global Epidemic of Metabolic Fatty Liver Disease.
Lee ECZ; Anand VV; Razavi AC; Alebna PL; Muthiah MD; Siddiqui MS; Chew NWS; Mehta A
Curr Cardiol Rep; 2024 Apr; 26(4):199-210. PubMed ID: 38376745
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.
Schneider CV; Schneider KM; Raptis A; Huang H; Trautwein C; Loomba R
Aliment Pharmacol Ther; 2024 May; 59(10):1271-1281. PubMed ID: 38500443
[TBL] [Abstract][Full Text] [Related]
38. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
Staufer K; Stauber RE
Biomedicines; 2023 Jul; 11(8):. PubMed ID: 37626604
[TBL] [Abstract][Full Text] [Related]
39. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.
Wu T; Ye J; Mo S; Ye M; Li X; Li Q; Wang W; Zheng Q; Luo K; Zhang Y; Tu S; Che D; Gong R; Chen X; Miu R; Shao C; Sun Y; Zhong B
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38695344
[TBL] [Abstract][Full Text] [Related]
40. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
Canivet CM; Faure S
Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
